Dummer R, Hauschild A, Pentheroudakis GCutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):129-131

Department of Dermatology, University of Kiel, Kiel, Germany.
Annals of Oncology (Impact Factor: 7.04). 05/2009; 20 Suppl 4(Supplement 4):129-31. DOI: 10.1093/annonc/mdp152
Source: PubMed
Download full-text


Available from: George Pentheroudakis, Aug 26, 2014
  • Source
    • "Accurate primary staging is therefore essential for developing an appropriate treatment strategy. Conventional techniques for staging include computed tomography (CT), magnetic resonance imaging, skeletal scintigraphy, and conventional X-ray [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose The aim of this systematic review was to systematically assess the potential patient-relevant benefit (primary aim) and diagnostic and prognostic accuracy (secondary aim) of positron emission tomography (PET) and PET/computed tomography (CT) in primary staging of malignant melanoma. This systematic review updates the previous evidence for PET(/CT) in malignant melanoma. Materials and methods For the first aim, randomized controlled trials (RCTs) investigating patient-relevant outcomes and comparing PET and PET(/CT) with each other or with conventional imaging were considered. For the secondary aim, a review of reviews was conducted, which was amended by an update search for primary studies. MEDLINE, EMBASE and four databases of the Cochrane Library were searched. The risk of bias was assessed using a modified QUADAS tool. Results No RCTs investigating the patient-relevant benefit of PET(/CT) and no prognostic accuracy studies were found. Seventeen diagnostic accuracy studies of varying quality were identified. For patients with American Joint Committee on Cancer (AJCC) stages I and II, sensitivity mostly ranged from 0 to 67%. Specificity ranged from 77 to 100%. For AJCC stages III and IV, sensitivity ranged from 68 to 87% and specificity from 92 to 98%. Conclusion There is currently no evidence of a patient-relevant benefit of PET(/CT) in the primary staging of malignant melanoma. RCTs investigating patient-relevant outcomes are therefore required. The diagnostic accuracy of PET(/CT) appears to increase with higher AJCC stages.
    Systematic Reviews 12/2012; 1(1):62. DOI:10.1186/2046-4053-1-62
  • Source
    • "NSCLC: proportion of T1-3N0M0 cases receiving surgery [20]. Melanoma: proportion of cases with Breslow thickness > 1 mm receiving sentinel node biopsy [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Population-based cancer registry studies of care patterns can help elucidate reasons for the marked geographic variation in cancer survival across Italy. The article provides a snapshot of the care delivered to cancer patients in Italy. Methods: Random samples of adult patients with skin melanoma, breast, colon and non-small cell lung cancers diagnosed in 2003-2005 were selected from 14 Italian cancer registries. Logistic models estimated odds of receiving standard care (conservative surgery plus radiotherapy for early breast cancer; surgery plus chemotherapy for Dukes C colon cancer; surgery for lung cancer; sentinel node biopsy for >1mm melanoma, vs. other treatment) in each registry compared to the entire sample (reference). Results: Stage at diagnosis for breast, colon and melanoma was earlier in north/central than southern registries. Odds of receiving standard care were lower than reference in Sassari (0.68, 95%CI 0.51-0.90) and Napoli (0.48, 95%CI 0.35-0.67) for breast cancer; did not differ across registries for Dukes C colon cancer; were higher in Romagna (3.77, 95%CI 1.67-8.50) and lower in Biella (0.38, 95%CI 0.18-0.82) for lung cancer; and were higher in Reggio Emilia (2.37, 95%CI 1.12-5.02) and lower in Ragusa (0.27, 95%CI 0.14-0.54) for melanoma. Conclusions: Notwithstanding limitations due to variations in the availability of clinical information and differences in stage distribution between north/central and southern registries, our study shows that important disparities in cancer care persist across Italy. Thus the public health priority of reducing cancer survival disparities will not be achieved in the immediate future.
    07/2012; 36(6). DOI:10.1016/j.canep.2012.06.006
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Advanced melanoma is a disease with a poor prognosis. Most of the currently available chemotherapy agents are ineffective. In contrast to other cancers, immune-based and novel, targeted therapies appear to have some effect in melanoma. Exciting research in the past few years holds hope for the future. We provide an overview of the current management principles of this condition with special emphasis on the emerging options in the systemic therapy of advanced disease.
    The National medical journal of India 23(1):21-7. · 0.78 Impact Factor
Show more